Patent US4258030A successfully refreshed from Google Patents.
US4258030A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Urokinase preparation for oral administration
Assignee: ZERIA-SHINYAKU KOGYO A Co OF JAPAN KK
•
Filing: 1979-03-07
•
Granted: 1981-03-24
•
Expires: 1999-03-07
Abstract
Abstract Disclosed is a urokinase preparation for oral administration which is effective for remedy of thrombosis such as cerebral thrombosis and cardiac infarction. This preparation comprises urokinase and, incorporated therein, an enzyme inhibitor.
Inventors
- 👤 Koji Sasaki
- 👤 Yasukazu Harada
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:58
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; C12N9/6462; A; A61; A61K; A61K38/00; A61K38/005; A61K47/00; A61K47/06; A61K47/16; A61K47/18; A61K47/183; C12Y; C12Y304/00; C12Y304/21; C12Y304/21073
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
51 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is a trypsin inhibitor extractable from human urine selected from the group consisting of mingin, minginin and urine trypsin inhibitor, together with a pharmaceutical carrier.
Claim 2
Dependent Claim
51 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is a trypsin inhibitor extractable from human urine selected from the group consisting of mingin, minginin and urine trypsin inhibitor, together with a pharmaceutical carrier.
Claim 3
Dependent Claim
35 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is soybean trypsin inhibitor, together with a pharmaceutical carrier.
Claim 4
Dependent Claim
35 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is soybean trypsin inhibitor, together with a pharmaceutical carrier.
Claim 5
Dependent Claim
33 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is aprotinin, together with a pharmaceutical carrier.
Claim 6
Dependent Claim
33 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is aprotinin, together with a pharmaceutical carrier.
Claim 7
Dependent Claim
49 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is selected from the group consisting of ε-aminocaproic acid, tranexamic acid, ε-guanidinocaproic acid, p-amidinobenzoic acid and p-guanidinobenzoic acid, together with a pharmaceutical carrier.
Claim 8
Dependent Claim
49 words
A pharmaceutical composition with antithrombotic action for oral administration comprising an effective amount of urokinase and an effective urokinase stabilizing amount of an enzyme inhibitor which is selected from the group consisting of ε-aminocaproic acid, tranexamic acid, ε-guanidinocaproic acid, p-amidinobenzoic acid and p-guanidinobenzoic acid, together with a pharmaceutical carrier.
Claim 9
Dependent Claim
28 words
The pharmaceutical composition as defined in claims 1 or 2 which comprises a ratio of enzyme inhibitor units to urokinase units of from about 1 to about 4.
Claim 10
Dependent Claim
24 words
The pharmaceutical composition as defined in claim 3 which comprises a ratio of aprotinin units per urokinase units of from about 1:500 to 1:50.
Claim 11
Dependent Claim
18 words
The pharmaceutical composition as defined in claim 6 wherein the ratio is from about 1:100 to about 1:50.
Claim 12
Dependent Claim
26 words
The pharmaceutical composition as defined in claim 4 which comprises an amount of from 2.5 to 250 μg of tranexamic acid per 25 units of urokinase.
Claim 13
Dependent Claim
28 words
The pharmaceutical composition as defined in claim 5 which comprises an amount of from about 100 to about 200 units of enzyme inhibitor per 50 units of urokinase.
Claim 14
Dependent Claim
21 words
The pharmaceutical composition as defined in claim 1, 2, 3 or 4 which is in the form of capsules or tablets.
Claim 15
Dependent Claim
22 words
The pharmaceutical composition as defined in claim 10 which is in the form of capsules or tablets coated wuth an enteric coating.
References Cited (Backward Citations)
US3726969A
Cited
US3919414A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-03-23 | 1984-09-22 | 1985-03-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-03-23 | 1988-09-22 | 1989-03-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-03-23 | 1992-09-22 | 1993-03-24 | $7700.00 | Window Closed / Lapsed |